DIA: Driving Insights to Action
Science:Life Sciences
In April 2021, the Regulatory Information Management (RIM) Working Group of DIA’s Regulatory Affairs Community issued Version 2.0 of the RIM Whitepaper that provides insights relating to eleven key regulatory capability areas including RIM implementation considerations, processes, and best practices. The Whitepaper also provides context for the RIM Reference Model in development. “One of the key aspects of the model is standardizing terminology and relationships between information,” explains IQVIA Senior Regulatory Affairs Director Donald Palmer in this conversation moderated by Ennov Director of Product Management Kathie Clark. “It puts the stake in the ground in terms of the basic data elements required to support regulatory in its business process and also other functional areas which depend on regulatory,” continues Venkatraman Balasubramanian, Senior Vice President, Life Sciences, Orion Innovation. “If we can put the best practices out there, we all align on the hope that this will allow industry to bring life-saving or life-improving medications and therapies to patients faster. We're hoping to make a big difference,” concludes Pat Shafer, Managing Director, FTI Consulting. Download Version 2.0 of the RIM Whitepaper.
DIAmond Session 203: “Innovation is Clearly Happening”: Next Generation Collaboration: Transforming the Industry
DIAmond Session 201: International Regulatory Convergence, Collaboration & Cooperation
Executive FDA Leadership Reviews & Previews PDUFA Reauthorization
“Biosimilars have at last come of age in the United States”
Mission, History & Opportunity Attracts New DIA Americas Leadership
Clinical & Real-World Data: Is AI the Missing Link?
TransCelerate Moves Clinical QMS from Vision to Conceptual Framework
Executive Director Shares New CTTI Strategic Plan to Improve Clinical Trials
Who Determines the Price of Medicines – and How?
“An Urgent Imperative Now to Learn Quickly”: DIA 2016 Co-Chair Dr. Gigi Hirsch
Industry-Patient Relations: Culture Change or Culture Shock?
Every Journey Begins with a First Step: DIA Patient Engagement
“Outbreaks are inevitable. Pandemics are preventable.” – DIA 2016 Keynote Speaker Dr. Larry Brilliant
Growing Irrelevancy of Pre- versus Post-Market Divide for EU Medical Devices
Crossroads in Europe: Access from a Market and HTA Perspective
A Visionary Takes the Helm at DIA Europe, Middle East & Africa (DIA EMEA)
Steps to Meet the “Big Quality” Challenge of “Big Data”
Innovation: Can it Span the “Efficacy versus Effectiveness Gap”?
Dr. Kemal Malik Ponders “Is Innovation Always the Answer?”
EMA Senior Medical Officer Explains “Access versus Evidence Tradeoff”
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
پادکست آذرخش مکری - azarakhsh mokri